Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
about
Options for empagliflozin in combination therapy in type 2 diabetes mellitusEmpagliflozinComparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysisClosing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisImpact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysisA Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesThe effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trialsThe role of empagliflozin in the management of type 2 diabetes by patient profile.Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysisSodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusA Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.Empagliflozin/linagliptin single-tablet combination: first-in-class treatment optionSodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Anti-diabetic effect of Alpinia oxyphylla extract on 57BL/KsJ db-/db- mice.Extra-glycaemic properties of empagliflozin.The effect of SGLT2 inhibitors on cardiovascular events and renal function.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.Implications of the EMPA-REG Trial for Clinical Care and Research.The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors: Benefit/Risk Balance.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.
P2860
Q26745771-B7AA8435-55D4-4D4A-B8DC-016327BFC8F3Q26773311-BE4039F5-FEB7-42AB-9E06-EDE18BCB4055Q28074573-CC8BBC2C-F8C8-4583-93F7-0A9DBD286E7EQ28075848-E6469CB1-3CEA-4CAC-B96D-5477FACC86BCQ28080114-9FBEA63B-E7E4-447E-A1E7-525C011BB3BBQ28553482-2FB87642-014B-4D27-AD7E-0CFED4382FD5Q33625568-4F227D1D-2CEC-4582-8224-F7054D417A24Q33767478-144170AD-1DBC-45F0-BC02-2FD9C0170686Q34161881-A0BB0585-1F41-4F85-A73D-B714C6D8BD78Q34198692-F1148D5A-CD5C-461F-B91A-A2C0C387BF03Q35260544-3028C0CD-3319-4DB1-8B94-BACB0845EDC3Q35592873-9DBBB810-3122-4B00-AAF4-6D8D51F4EC69Q35911236-45CF0253-2B3B-4C4B-963A-9F5165586242Q36301818-3FE3001C-28C4-4848-B18C-F1726087BE6CQ36357997-3D6EF75E-6563-4CE9-A23C-E5C28C487402Q36592820-9D9AFE10-07D1-4893-AB41-897396E17FEFQ36960633-0DDBBBDA-A30B-4A7B-B89E-79DFCCE5266AQ37060855-3FB87B83-6078-4D9E-B50D-9D7BF231B18EQ37308941-8FE59E8E-DAD0-4861-9976-CD3742BD60B3Q37722896-23717FB5-CCCC-4ACE-8FAA-6D53FE180728Q37734730-2487B368-4C66-491C-A237-7A2F43EF783FQ38494441-29489C3F-1DAF-4718-AA60-BED8F532C537Q38614488-9A8A7A0D-1E95-4CA7-9FA0-14ED84802E33Q38619164-5E9EAD3D-3C41-490C-ABA1-2A2FEB03E9DAQ38638523-7358BAB7-7CC9-41B0-A4D0-ECAD82E7B4F4Q38730067-183CD8F7-D238-452A-A559-C1E0E6424333Q38734956-7F102449-E195-4E44-96A0-DE92EB9DD007Q38783203-B3BE1843-F5A7-447D-B316-2CCBB994172DQ38796262-087FCCCF-538D-4621-97B0-F1CA7AFE200CQ38798623-2649EF41-97C0-410D-95F5-3BE5591A6A5CQ38870752-9271801E-8279-45B1-8D12-ECDDB600731CQ38906041-403E82CB-194F-4DB7-9087-75BC5A51BE76Q38931842-CCB87C71-BAE6-40EA-AFD1-9C55AE9D2EEAQ38936746-DC62250C-C959-40B1-A7FB-226CC1174CDFQ39000172-34DA245E-3916-493F-B5F4-7F323EA22773Q39000587-6E4AA365-7B3D-425C-90C3-BCC7E6A698F6Q39007677-37FBB2BE-28BC-4545-9E85-C14E457F8954Q39189383-F7AEE93E-EA8B-4FB6-B721-A41A70291B00Q39300057-F45E3FEB-3EC0-4DE1-8855-BA69393889B9Q39300071-2A5000DA-C000-4A82-A27F-901A0F20FD9F
P2860
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of empagli ...... atic review and meta-analysis.
@ast
Efficacy and safety of empagli ...... atic review and meta-analysis.
@en
type
label
Efficacy and safety of empagli ...... atic review and meta-analysis.
@ast
Efficacy and safety of empagli ...... atic review and meta-analysis.
@en
prefLabel
Efficacy and safety of empagli ...... atic review and meta-analysis.
@ast
Efficacy and safety of empagli ...... atic review and meta-analysis.
@en
P2093
P2860
P50
P356
P1476
Efficacy and safety of empagli ...... atic review and meta-analysis.
@en
P2093
E Athanasiadou
K Papatheodorou
P2860
P304
P356
10.1111/DOM.12307
P577
2014-05-28T00:00:00Z